Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Hamid, Omid; Robert, Caroline; Daud, Adil; Stephen Hodi, F.; Hwu, Wen-Jen; Kefford, Richard; D. Wolchok, Jedd; Hersey, Peter; W. Joseph, Richard; S. Weber, Jeffrey; Dronca, Roxana; C. Gangadhar, Tara; Patnaik, Amita; M. Zarour, Hassane; M. Joshua, Anthony; Gergich, Kevin; Elassaiss‐Schaap, Jeroen; P. Algazi, Alain; Mateus, Christine; D. Boasberg, Peter; C. Tumeh, Paul; Chmielowski, Bartosz; Ebbinghaus, Scot; Li, Xiaoyun; Kang, Sunyu; Ribas, Antoni

doi:10.1056/nejmoa1305133

Public

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Published in New England Journal of Medicine • Jun 2, 2013

Authors:

Omid Hamid

Caroline Robert

Adil Daud

Abstract

BACKGROUND: The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. We tested the anti-PD-1 antibody lambrolizumab (previously known as MK-3475) in patients with advanced melanoma. METHODS: We administered lambrolizuma...

Subject

Medicine

Ipilimumab

Rash

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!